Risk of progression of Barrett's esophagus in patients with cirrhosis

被引:3
|
作者
Apfel, Tehilla [1 ]
Lopez, Rocio [1 ]
Sanaka, Madhusudhan R. [1 ]
Thota, Prashanthi N. [1 ]
机构
[1] Cleveland Clin Fdn, Dept Gen Internal Med, Cleveland, OH 44195 USA
关键词
Liver cirrhosis; Barrett's esophagus; Dysplasia; Esophageal neoplasm; Progression; NONALCOHOLIC FATTY LIVER; HIGH-GRADE DYSPLASIA; GASTROESOPHAGEAL-REFLUX; METABOLIC SYNDROME; ADENOCARCINOMA; VARICES; METAANALYSIS; ADIPOKINES; DISEASE;
D O I
10.3748/wjg.v23.i18.3287
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM To study Barrett's esophagus (BE) in cirrhosis and assess progression to esophageal adenocarcinoma (EAC) compared to non-cirrhotic BE controls. METHODS Cirrhotic patients who were found to have endoscopic evidence of BE confirmed by the presence of intestinal metaplasia on histology from 1/1/2000 to 12/1/2015 at Cleveland Clinic were included. Cirrhotic patients were matched 1: 4 to BE controls without cirrhosis. Age, gender, race, BE length, hiatal hernia size, Child-Pugh (CP) class and histological findings were recorded. Cases and controls without high-grade dysplasia (HGD)/EAC and who had follow-up endoscopies were studied for incidence of dysplasia/EAC and to assess progression rates. Univariable conditional logistic regression was done to assess differences in baseline characteristics between the two groups. RESULTS A total of 57 patients with cirrhosis and BE were matched with 228 controls (BE without cirrhosis). The prevalence of dysplasia in cirrhosis and controls were similar with 8.8% vs 12% with low grade dysplasia (LGD) and 12.3 % vs 19.7% with HGD or EAC (P = 0.1). In the incidence cohort of 44 patients with median follow-up time of 2.7 years [interquartile range 1.0, 4.8], there were 7 cases of LGD, 2 cases of HGD, and 2 cases of EAC. There were no differences in incidence rates of HGD/ EAC in nondysplastic BE between cirrhotic cases and noncirrhotic controls (1.4 vs 1.1 per 100 person-years, P = 0.8). In LGD, cirrhotic patients were found to have higher rates of progression to HGD/EAC compared to control group though this did not reach statistical significance (13.7 vs 8.1 per 100 person-years, P = 0.51). A significant association was found between a higher CP class and neoplastic progression of BE in cirrhotic patients (HR = 7.9, 95% CI: 2.0-30.9, P = 0.003). CONCLUSION Cirrhotics with worsening liver function are at increased risk of progression of BE. More frequent endoscopic surveillance might be warranted in such patients.
引用
收藏
页码:3287 / 3294
页数:8
相关论文
共 50 条
  • [21] INFLUENCE OF PERSISTENT LGD ON PROGRESSION IN PATIENTS WITH BARRETT'S ESOPHAGUS
    Blevins, Christopher H.
    Dierkhising, Ross
    Otaki, Fouad
    Johnson, Michele L.
    Ravikumar, Naveen Prasad Gopalakrishnan
    Buttar, Navtej S.
    Katzka, David A.
    Iyer, Prasad G.
    GASTROENTEROLOGY, 2017, 152 (05) : S456 - S457
  • [22] CIRRHOSIS AND BARRETT'S ESOPHAGUS (BE): DIAGNOSIS AND PREVALENCE
    Tyberg, Amy M.
    Sundararajan, Subha
    Zeffren, Noam
    Ando, Yumi
    Aden, Brandon
    Jacobson, Ira M.
    Gambarin-Gelwan, Maya
    HEPATOLOGY, 2011, 54 : 1270A - 1270A
  • [23] Risk factors, DNA damage, and disease progression in Barrett's esophagus
    Olliver, JR
    Hardie, LJ
    Gong, Y
    Dexter, S
    Chalmers, D
    Harris, KM
    Wild, CP
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (03) : 620 - 625
  • [24] Goblet Cell Density and Risk of Neoplastic Progression in Barrett's Esophagus
    Bansal, Ajay
    McGregor, Douglas H.
    Rao, Deepthi S.
    Singh, Mandeep
    Gaddam, Srinivas
    Cherian, Rachel
    Anand, Oksana
    House, John
    Shipe, Tracy
    Singh, Vikas
    Wani, Sachin B.
    Gupta, Neil
    Rasiogi, Amit
    Sharma, Prateek
    GASTROENTEROLOGY, 2011, 140 (05) : S306 - S306
  • [25] Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus
    Rudolph, RE
    Vaughan, TL
    Storer, BE
    Haggitt, RC
    Rabinovitch, PS
    Levine, DS
    Reid, BJ
    ANNALS OF INTERNAL MEDICINE, 2000, 132 (08) : 612 - +
  • [26] Segment length and risk for neoplastic progression in patients with Barrett esophagus - Response
    Rudolph, RE
    Vaughan, TL
    Storer, B
    ANNALS OF INTERNAL MEDICINE, 2000, 133 (09) : 748 - 748
  • [27] Glandular Irregularity and Paneth Cell Metaplasia Predict the Progression Risk of Patients with Barrett's Esophagus
    Chen, Tiane
    Zhang, Yong
    Chen, Guoli
    LABORATORY INVESTIGATION, 2024, 104 (03) : S686 - S687
  • [28] Pyloroplasty and the risk of Barrett's esophagus in patients with gastroparesis
    Alkhayyat, Motasem
    Sanghi, Vedha
    Qapaja, Thabet
    Butler, Robert
    Rouphael, Carol
    McMichael, John
    Goldblum, John
    Sanaka, Madhusudhan R.
    Thota, Prashanthi N.
    DISEASES OF THE ESOPHAGUS, 2020, 33 (11)
  • [29] RISK OF EROSIVE ESOPHAGITIS AND BARRETT'S ESOPHAGUS IN PATIENTS WITH A FIRST-DEGREE RELATIVE WITH BARRETT'S ESOPHAGUS
    Havlichek, Daniel H.
    Kamboj, Amrit K.
    Wang, Kenneth K.
    Iyer, Prasad G.
    Katzka, David A.
    Leggett, Cadman L.
    GASTROENTEROLOGY, 2021, 160 (06) : S246 - S246
  • [30] The absence of dysplastic progression in patients with Barrett's esophagus receiving omeprazole
    Randll, CW
    Ostrower, VS
    Stump, DL
    GASTROENTEROLOGY, 1999, 116 (04) : A289 - A289